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Abstract
Aim: Arterial extracellular matrix (ECM) remodeling by matrix metalloproteinases (MMPs) is one of the major hallmarks of athero-
sclerosis. Mimecan, also known as osteoglycin has been implicated in the integrity of the ECM. This study assessed the validity of an 
enzyme-linked immunosorbent assay (ELISA) developed to measure a specific MMP12-derived fragment of mimecan, MMCN-151, in 
apolipoprotein-E knockout (ApoE-KO) mice.
Methods and results: A mouse monoclonal antibody raised against MMCN-151 was used to develop a competitive ELISA. The assay 
was validated using samples from 20 ApoE-KO and 20 wild type [C57 BL/6] male mice fed a normal or high-fat diet (HFD) for up to 
20 weeks. The technical reliability of the assay was established with intra-assay variability ,2% and inter-assay variability ,10%. The 
lowest limit of quantification of MMCN-151 was 0.5 ng/ml. ApoE-KO mice fed a HFD for 20 weeks had four-fold increased circulating 
levels of MMCN-151 compared to baseline, whereas MMCN-151 levels in control mice on HFD increased two-fold compared with 
baseline. After 10 weeks of a HFD, a significant difference in MMCN-151 levels was observed between ApoE-KO and control mice 
(P = 0.005) and became more significant at 20 weeks (P = 0.002).
Conclusions: The newly developed assay is a reliable detector of MMCN-151 levels which ultimately may be useful indicators of arte-
rial remodeling in patients affected by atherosclerotic disease.
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Introduction
Even though research into the treatment of 
 cardiovascular diseases (CVD) has advanced in recent 
years and many diverse therapeutic approaches have 
been developed, CVD still remains the leading cause 
of death in most parts of the world.1  Atherosclerosis 
is one of the major underlying causes of cardio-
vascular-related deaths. In humans, atherosclerotic 
plaques consist of a fibrous cap mainly composed 
of smooth muscle cells (SMCs) and excessive extra-
cellular matrix (ECM).2 Fibrillar collagens such as 
type I and type III are the most predominant proteins 
of the ECM while the rest of the ECM is composed of 
proteoglycans such as mimecan, biglycan, decorin, 
perlecan and versican.3 Type III collagen is thought 
to be associated with extensibility of the wall of the 
artery, whereas type I collagen may be responsible 
for arterial stiffness.4,5 The ECM is critically impor-
tant for maintaining the physicochemical structure 
of the artery, providing tensile strength as well as 
viscoelastic properties.6 The ECM also contributes 
to cellular and organ functions. Proteins making 
up the ECM in the fibrous cap of an atherosclerotic 
plaque may be degraded at least in part by matrix 
metallo proteases (MMPs) when these are present 
in abnormally high quantities. MMPs are produced 
by macrophage foam cells and other inflammatory 
cells. As a result of MMP activity, the fibrous cap 
may be eroded, releasing the highly thrombogenic 
lipid core of the plaque to the circulation, resulting 
in thrombus formation.7–10 MMP-12 in particular 
has a broad range of substrates, especially collagen 
type I, III, elastin and proteoglycans. Recently, a 
proteoglycan, mimecan, also known as osteoglycin, 
has been implicated in regulation of collagen fibril-
logenesis, artheriogenesis and in regulation of left 
ventricular mass.11–13 Mimecan is one of the small 
leucin-rich proteoglycans (SLRP). Other members 
of this family are biglycan, decorin, fibromodulin 
and lumican.
The atherosclerotic plaque is continuously remod-
elled, releasing in the process a range of degradation 
products of ECM proteins, the so-called neoepitopes.14 
These neoepitopes may be specific to the tissue of ori-
gin and therefore may prove useful as novel molec-
ular biochemical markers. The neoepitope-based 
biochemical markers measurable in urine and serum 
are receiving increased attention for their diagnostic 
and prognostic potential.15
Previously, assays determining type III  collagen 
synthesis by measurements of the N-terminal pep-
tide (PIIIP) demonstrated significant increases in 
serum PIIIP in atherosclerotic patients compared with 
 controls.16 While collagen synthesis may be impor-
tant in plaque progression, an important factor lead-
ing to plaque instability is degradation of collagens 
in the atherosclerotic lesion, especially in the areas 
of plaque shoulders by proteases such as MMPs pro-
duced locally by macrophages and other cells.17–20 We 
previously developed biochemical markers of type I 
and type II collagen degradation by proteases. These 
markers are now being used in preclinical and clini-
cal settings to evaluate the efficacy of intervention in 
osteoporosis and osteoarthritis.21–23
The purposes of the current study were to: (1)  inves-
tigate specific ECM protein fragments released from 
atherosclerotic plaques; (2) perform in vitro protein 
digestion by MMPs and identify the released frag-
ments by mass-spectrophotometry (3) develop an 
enzyme-linked immunosorbent assay (ELISA) based 
on a specific monoclonal antibody against a spe-
cific peptide of mimecan generated by the action of 
MMP-12 (4) validate the assay in the gold standard 
mouse model of atherosclerosis, the apolipoprotein E 
knock-out (ApoE KO) mouse.
Material and Methods
In vitro cleavage
Recombinant mouse mimecan (cat. No. 2949-
MC-050, R&D Systems, Denmark) was cleaved 
with activated MMP-12 (cat.no.ab54058, Abcam, 
UK). To facilitate MMP-12 cleavage of mimecan, 
1 mg/mL mimecan was filtered to remove proteins 
below 10,000 kDa (Microcon Ultracel YM-10, cat. 
no. 42407, Millipore, Billerica, MA, USA) after 
which 100 µg mimecan was mixed with 1 µg of 
enzyme (MMP-12) in MMP buffer (100 mM Tris-
HCl, 100 mM NaCl, 10 mM CaCl
2
, 2 mM Zn ace-
tate, pH 8.0). As a control, 100 µg of mimecan was 
mixed with MMP buffer only. The solutions contain-
ing mimecan were incubated for 24 hrs at 37 °C. 
All cleavage activity was terminated using EDTA. 
Finally the cleavage was verified visually using the 
SilverXpress® Silver Staining Kit (cat. no. LC6100, 
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Invitrogen, Carlsbad, Ca, USA) according to the 
manufacturer’s instructions.
Peptide identification
Peptide fragments in the in vitro cleaved samples 
were identified using matrix-assisted laser desorption 
time of flight mass spectrometry (MALDI-TOF MS) 
and liquid chromatography (LC) coupled with elec-
tro spray ionization (ESI) tandem mass spectrometry 
(LC-MS/MS). MALDI-TOF samples were purified 
using C18 zip-tips (cat.no.ZTC18SO24, Millipore, 
Billerica, MA, USA) according to the manufacturer’s 
specifications and 0.1 µg of material was eluted onto a 
MTP 384 ground steel target plate (Bruker- Daltonics, 
Bremen, Germany). MALDI tandem mass spectra 
were recorded on a Bruker ultraflex MALDI-TOF/
TOF mass spectrometer (Bruker- Daltonics,  Bremen, 
Germany) in positive ion reflector mode. Mass spec-
tra were externally calibrated in the m/z range of 
800−4000 using peptides generated by tryptic diges-
tion of bovine β-lactoglobulin. The m/z software “Flex-
analysis” (Bruker-Daltonics,  Bremen,  Germany) was 
used to analyze spectra. LC-MS samples were ultra-
filtrated to remove proteins above 10 kDa, the pH was 
adjusted to 2.0 using formic acid, and a 4 µL sample 
was analyzed by LC-MS/MS. LC was performed on 
a nanoACQUITY UPLC BEH C18 column (Waters, 
Milford, MA, USA) using a formic acid/ acetonitril 
gradient. MS and MS/MS were performed on a Synapt 
High Definition Mass Spectrometry quadruple time of 
flight MS (QUAD-TOF; Waters, Milford, MA, USA), 
with an acquisition range of 350–1600 m/z in MS and 
50–2000 m/z, in MS/MS. The software “ProteinLynx 
Global SERVER (PLGS)” (Waters, Milford, MA, 
USA) was used to analyze spectra and generate peak 
lists. To identify peptides, MS and MS/MS data were 
searched against the mimecan (FASTA) protein data-
base using the Mascot 2.2 (Matrix Science, Boston, 
MA, USA) software with either the MALDI-TOF/
TOF or ESI-QUAD-TOF settings.
Selection of peptide for immunizations
The first six amino acids of each free end of the pep-
tide sequences identified by MS were regarded as 
neo-epitopes generated by the protease in question. 
All obtained protease-generated sequences were ana-
lyzed for homology and distance to other cleavage 
sites and then blasted for homology using the NPS@: 
network protein sequence analysis.
reagents and peptides
All reagents were standard high-quality chemicals 
from companies such as Merck and Sigma Aldrich. 
The following synthetic peptides used for monoclo-
nal antibody production and validation were pur-
chased from the Chinese Peptide Company, Beijing, 
China: (a) immunogenic peptide: Ovalbumine-
GGC-EDIEDGTFSK (OVA), (b) screening peptide 
EDIEDGTFSK, (c) de-selection peptide EDIEDGTF-
SKL which had been elongated with one amino acid 
in the C-terminus. Peptide conjugation reagents were 
obtained from Pierce, Thermofisher, (Denmark).
Buffers
Buffer used for dissolving the coating peptide 
was composed of the following: 40 mM NaHPO4, 
12HO, 7 mM KH PO4, 137 mM NaCl, 2,7 mM KCl, 
25 mM EDTA, 0,1% Tween 20, 1% BSA, 10% sor-
bitol, pH 7.
Buffer containing the following chemicals was 
used for incubation of the serum/plasma: 100 mM 
TRIZMA, 0,05% Tween 20, 0,1% BSA, 0,36% 
 Bronidox L5, pH 7,4. For washing steps, we used a 
buffer composed of: 25 mM TRIZMA, 50 mM NaCl, 
0,036% Bronidox L5, 0,1% Tween 20, and reaction 
stopping buffer composed of 0,1% H SO4.
ELISA-plates used for the assay development 
were streptavidin-coated from Roche Diagnostics 
cat.: 11940279. All ELISA plates were analyzed with 
the ELISA reader from Molecular Devices, Spectra-
Max M, (CA, USA).
Development of the eLISA
We followed the previously described methods for 
monoclonal antibody development.24 Briefly, 4- 
6-week-old Balb/C mice were immunized subcuta-
neously with 200 µl emulsified antigen and 50 µg 
MMCN-151 (EDIEDGTFSK). Consecutive immuni-
zations were performed at 2-week intervals until stable 
sera titer levels were reached in Freund’s incomplete 
adjuvant. The mice were bled from the 2nd immu-
nization on. At each bleeding, the serum titer was 
detected and the mouse with the highest antiserum 
titer was selected for fusion. The selected mouse was 
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rested for 1 month followed by intravenous boosting 
with 50 µg MMCN-151 in 100 µl 0.9% sodium chlo-
ride solution 3 days before isolation of the spleen for 
cell fusion.
Fusion
The fusion procedure previously described25 was 
followed with SP2/0 as myeloma cells. The fusion 
cells were cloned in 35-mm cell culture dishes using 
the semi-solid medium method and the dishes were 
incubated in a CO
2
-incubator. Next, clones were 
plated into 16 96-well microtiter plates and left 
for three days, followed by screening of culture 
supernatants.
Antibody screening
Supernatants were screened in a competitive ELISA 
setting. Peptide EDIEDGTFSK was used as the 
selection peptide and the EDIEDGTFSKL as the 
elongated peptide. Cell lines specific to the selec-
tion peptide and without cross-reactivity to the elon-
gated peptide were selected and the antibodies were 
purified.
MMcn-151 eLISA methodology
In preliminary experiments, we optimized the 
reagents, their concentrations and the incubation peri-
ods by performing several checkerboard analyses. 
The MMCN-151 ELISA was developed as follows: 
A 96-well ELISA plate pre-coated with streptavidin 
was further coated with 1.25 ng/ml of the synthetic 
peptide Biotin-EDIEDGTFSK which had been dis-
solved in PBS-TBE buffer at 20 °C for 30 min by con-
stant shaking at 300 rpm. After the plate was washed 
five times in washing buffer, 20 µl of sample was 
added, followed by 100 µl of peroxidase conjugated 
anti-human mAb-MMCN-151 solution (30 ng/mL). 
The plate was incubated for 1 h at 20 °C in 100 mM 
Tris-BT buffer during which time it was shaken at 
300 rpm.
The plate was again washed five times followed by 
the addition of 100 µl tetramethylbenzinidine (TMB) 
(Kem-En-Tec cat.438OH). The plate was incubated 
for 15 min in darkness and shaken at 300 rpm. To cease 
the reaction,100 µl of stopping solution (95%–97% 
H
2
SO4, Merck Cat. No.: 1.00731) was added and the 
plate was analyzed in the ELISA reader at 450 nm 
with 650 nm as the reference.
Standards
A standard curve was obtained by serial dilution of 
biotinylated-MMCN-151. Standard concentrations 
were 0, 0.3125, 6.25, 12.5, 25, 50, 100, 200 ng/mL.
Samples for testing native reactivity  
of the antibodies
For assay development and validation, serum from 
healthy adult volunteers aged 23–50 years and of 
either gender was used. The positive control used in 
the assays was the material obtained from in vitro 
cleavage of mimecan with purified human MMP-12. 
We also tested serum samples from different species 
including mouse, rat, rabbit, monkey and pig to deter-
mine the level of interspecies cross-reactivity.
Technical evaluation of the eLISA
All ELISAs were developed according to the  Nordic 
Bioscience standard operating procedures which 
require:
Intra-assay precision and accuracy: 10 indepen-
dent runs on 10 different plates were performed on 
the test samples of human serum.
Inter-assay precision and accuracy: This was 
determined by 10 independent assay runs of each 
validation sample on 10 different plates.
Lower Limit of Detection (LLD): In an analyti-
cal run, 40 determinations were made of the lowest 
standard (the zero standards). This was repeated three 
times. On each plate, the LLD was estimated using 
the following formula: LLD = mean − 3 × SD. The 
average LLD concentration was calculated using the 
4-parametric-fit equation.
Recovery: Four different samples covering more 
than 50% of the standard curve, from all dilutions, 
were back-calculated from diluted to undiluted sam-
ples in order to estimate the recovery percentage.
Animal samples
20 ApoE KO and 20 wild type C57 BL/6 male mice 
aged 10 weeks from Taconic, Europe A/S (Lille 
Skensved, Denmark) were fed either a standard 
maintenance diet of Altromin (product ID: 1320, 
Brogaarden, Denmark) or ad libitum, a high fat diet 
containing 60% fat (product ID: D12492, Brogaarden, 
Denmark). Ethical guidelines for experimental inves-
tigations in animals were followed and the protocol 
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was approved by the local Experimentation Ethics 
Committee “Dyreforsogstilsynet”, in accordance 
with European Commission guidelines. The study 
also conformed to the “Guide for care and use of lab-
oratory animals” published by the US National Insti-
tutes of Health. When mice were aged 10 (baseline), 
20 and 30 weeks, plasma samples were collected by 
blood sampling using retro orbital puncture or, in the 
case of sacrifice at weeks 20 or 30, by syringe aspi-
ration of around 1 mL from the jugular vein. Blood 
heparinized with lithium heparin was centrifuged and 
the plasma frozen at −20 °C until assayed. Plasma 
cholesterol was measured by enzymatic assays using 
an analyzer from Molecular Devices, SpectraMax M, 
(CA, USA).
Densitometry
Densitometry measurements were performed using 
UN-SCAN-IT Version 6.1 from Silk Scientific, 
according to the manufacturer’s guidelines.
histology image analysis
Sections of mouse aorta were stained with Alcian 
blue, a standard staining which binds to glycosamino-
glycans on proteoglycabs. Stained mouse sections 
were analysed using Visiopharm software Version 
3.2.8.0 (Hørsholm, Denmark). The Visiopharm appli-
cation quantified specific tissue areas containing posi-
tive staining. Images were acquired using the Pixelink 
PL-A623C microscope digital camera.
Statistical analysis
For assay validation, optical density (OD) was matched 
against analyte concentrations by applying a four-
 parameter logistic regression to the calibration curve. 
Average, standard deviations, percentage coefficient 
of variation (%CV), and differences from theoretical 
values were calculated for all standards and samples. 
Quantitative data were analyzed using GraphPad 
Prism 5 (GraphPad Software, San Diego, CA, USA). 
 Significant differences between means were deter-
mined using the Student’s two-tailed unpaired t-test, 
not assuming Gaussian distribution. Correlations 
between serum MMCN-151 values and the rest of the 
variables studied were analyzed with Pearson’s two-
tailed test. Data were expressed as mean ± standard 
error of the mean and differences were considered 
significant at a P level of 0.05 or lower.
Results
ELISA technical specifications
The antibody, raised against MMCN-151 antigen, 
which had the best native reactivity, affinity and stabil-
ity generated after the fusion of spleen and myeloma 
cells was NB206-15B6-F8. Consequently, this clone 
was chosen for antibody purification and the subse-
quent development of the ELISA.
Standard curve and recovery
A typical standard curve is presented in  Figure 1A, 
showing chosen standards and the 4- parametric fit 
equation for determination of sample concentration.
Determination of the linearity or recovery by dilu-
tion in different samples resulted in the following: 
the average recoveries back-calculated from sam-
ples diluted 1:1, 1:2, 1:4, 1:8 and 1:16 to undiluted 
sample were close to 100% and within the recom-
mended ±10% (data not shown).
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Figure 1. (A) Example of a 4-parametric fitted standard curve in a 
 competitive eLISA setting with peptide concentrations of 0, 3.125, 6.25, 
12.5, 25, 50, 100 and 200 ng/ml. (B) competitive eLISA test of MMcn-
151 antibody reaction towards free peptide, elongated peptide, mimecan 
cleaved with MMP12 and intact mimecan. The x-axis is representative 
of the concentrations of free and elongated peptide. concentrations of 
samples containing mimecan and mimecan cleaved with MMP12 are 
43 ug/ml as the highest concentration followed by 2-fold dilutions of 
samples.
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To ensure that the antibody was specific to the 
 neo-epitope of mimecan and was not cross-reacting 
with either elongated peptide or whole mimecan, we 
compared the assay reactivity of MMP-12 cleaved 
mimecan with uncleaved mimecan and elongated 
peptide. As illustrated in Figure 1B, the MMCN-151 
antibody was specific to the synthetic-free peptide, 
resulting in the inhibition of the signal from approxi-
mately 2.0 optical density (OD) (450–650) to 0.5. 
Similar results were seen for mimecan cleaved in vitro 
by MMP12, where the signal inhibition followed the 
synthetic peptide curve. Moreover, no inhibition of 
the signal was detected in the sample containing the 
synthetic peptide elongated with one amino-acid. Very 
weak competition with intact mimecan was observed 
at the highest concentration.
The lowest limit of detection (LLD), defined as the 
lowest analyte concentration that could be quantitatively 
determined with suitable accuracy, was 0.5 ng/ml.
Precision—intra-assay variability  
and inter-assay variability
The average intra-assay variability, calculated as the 
average % coefficient of variation (%CV) in readings 
of 10 replicates of four human serum samples which 
had an average MMCN-151 concentration of 5 ng/ml, 
was 1.3%. The 10 replicates of one rat serum sample 
had an average MMCN-151 concentration of 13 ng/ml 
with an average intra-assay variability of 1.1%.
Inter-assay mean %CVs were determined from the 
same sets of samples as the intra-assay and standards 
but on 10 different plates on 10 different days. The 
average inter-assay variability, between the highest 
and lowest levels detected, was 10.2%.
Plasma MMCN-151 values reflect early 
atherosclerosis in Apoe KO mice
Plasma MMCN-151 levels, measured in ApoE KO 
mice and in the C57 bl6 controls at baseline and 
after 10 or 20 weeks of feeding on either normal diet 
(ND) or HFD, are shown in Figure 2A and B, respec-
tively. The effect of the two diets on mimecan levels 
in ApoE KO mice compared with control mice at 
20 weeks is presented in Figure 2C.
The one-way ANOVA was significant (P , 0.0001) 
at 10 and 20 weeks in both the standard diet group and 
in HFD group. Results of MMCN-151 levels at 10 and 
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Figure 2. Plasma levels of MMcn-151 in control (ctrl) and Apoe-KO 
mice, at baseline (BL), after 10 weeks and after 20 weeks of feeding 
either standard chow (A) or high fat diet (B), and (c) effect of diet on 
circulating levels of MMcn-151 neoepitope after 20 weeks of feeding.
notes: *P , 0.05; **P , 0.01; ***P , 0.001.
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Total proteoglycan content correlates 
with plasma MMcn-151 levels
Visiopharm evaluation of the percentage of pixel 
intensity in a certain area, showed the total proteogly-
can content in the abdominal aorta of ApoE KO mice 
after 20 weeks of a HFD was significantly correlated 
with plasma MMCN-151 levels (Fig. 5).
Discussion
Biochemical markers consisting of protein degrada-
tion fragments from tissues undergoing extensive 
remodeling may indicate disease pathology and may 
be useful for diagnostic and prognostic purposes. 
 Furthermore, these markers may detect changes 
resulting from intervention strategies and serve as 
surrogate markers of efficacy.26
The current study is, to our knowledge, the first 
to present the development of an assay detecting a 
specific fragment of mimecan (also known asosteo-
glycin) generated by MMP-12. Our main findings 
were: (1) The monoclonal antibody selected for assay 
development was highly specific towards MMCN-
151, a mimecan neo-epitope generated by MMP-12. 
When tested in a competitive ELISA setting the anti-
body did not indicate cross-reactivity with the syn-
thetically generated form of the epitope elongated by 
one amino-acid, nor to uncleaved mimecan from the 
in vitro test; (2) The MMCN-151 assay had strong 
native reactivity towards human serum and plasma 
Table 1. Levels of circulating MMcn-151 peptide after 
10 and 20 weeks.
A.
standard  
diet
controls Apoe-KO P (Apoe KO 
vs. controls)
10 weeks 5.7 ng/ml 8.8 ng/ml P , 0.05
20 weeks 10.4 ng/ml 9.1 ng/ml ns
B.
High fat diet controls Apoe-KO P (Apoe KO 
vs. controls)
Standard diet 5.3 ng/ml 12.1 ng/ml P , 0.001
high fat diet 10.2 ng/ml 18.2 ng/ml P , 0.001
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Figure 3. cholesterol levels measured in mice plasma at baseline (BL) 
and after 20 weeks of feeding normal diet (nD) or high fat diet (hFD) 
in either control mice (ctrl) or in apolipoportein-e knock-out (Apoe-KO) 
mice.
20 weeks are shown in Table 1 below. At 10 weeks 
of feeding, MMCN-151 values were already signifi-
cantly increased (P . 0.001) in ApoE KO animals fed 
HFD compared to their controls and this difference 
was even more prominent at 20 weeks. At 20 weeks, 
there was no significant difference in control mice fed 
standard or HFD.
In the HFD groups, the levels of circulating MMCN-
151 were significantly higher (P = 0.002) in ApoE-KO 
mice than in HFD-fed controls after 20 weeks. No 
changes in MMCN-151 levels were seen in animals 
consuming a ND over 20 weeks (Fig. 2C).
Plasma cholesterol levels in control  
and Apoe KO mice
Cholesterol levels in ApoE KO and control mice at 
baseline and after 20 weeks of feeding on either a 
normal or HFD are illustrated in Figure 3.  Cholesterol 
levels increased significantly between baseline and 
the 20-week timepoint in control mice fed a HFD 
(P , 0.001), but not in mice fed a ND. In ApoE KO 
animals, cholesterol increased significantly between 
baseline and after 20 weeks of a ND (P = 0.001) and 
aHFD (P = 0.001). Furthermore, cholesterol levels 
were significantly higher (P , 0.001) in ApoE KO 
than control mice at baseline, and in ApoE KO mice 
fed either a ND or HFD. (P , 0.001).
The linear relationship between plasma MMCN-
151 values and total cholesterol after 20 weeks of 
a HFD in control mice (r = 0.48; P = 0.276), and 
ApoE-KO animals (r = 0.04; P = 0.931) is shown in 
Figure 4.
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and due to sequence homology also to rat and mouse 
sera and plasma; (3) A technically robust assay was 
developed with acceptable inter-, and intra-assay vari-
ation, dilution recovery and a low limit of  detection; 
(4) In the in vivo part of the study, MMCN-151 
plasma levels were significantly higher in mice fed 
a HFD for 20 weeks than those fed a normal diet. 
Furthermore, plasma levels of MMCN-151 in ApoE 
KO mice were significantly elevated at baseline, after 
10 and 20 weeks of feeding compared with levels in 
control mice; (5) There was no significant correlation 
between MMCN-151 and plasma cholesterol levels 
after 20 weeks of feeding.
Selection of clones and eLISA 
development
Characterization of the selected monoclonal anti-
body revealed strong reactivity towards human and 
rodent sera and plasma. Additionally, the antibody 
 demonstrated specificity towards the MMCN-151 
peptide, whether generated synthetically or in vitro 
by cleavage of mimecan by MMP-12, indicating that 
the antibody recognizes this particular peptide of 
mimecan in native samples. This was confirmed by 
the experiments showing no cross-reactivity towards 
the elongated synthetic peptide or to the intact mime-
can protein.
Plasma MMcn-151 in atherosclerosis  
in Apoe KO mice
In the ApoE KO model of atherosclerosis, plasma 
MMCN-151 levels increased significantly between 
baseline and 10 weeks, and between 10 weeks and 
20 weeks, of feeding on a HFD. The same pattern was 
observed in control mice, but in this group of animals 
there was only a significant increase between base-
line and 20 weeks of feeding on a HFD. In general, 
levels of MMCN-151 were higher at all time-points 
in ApoE KO mice than in control animals. This find-
ing is supported by the literature, which shows ApoE 
mice develop atherosclerosis over time even when 
fed only a normal diet.
The study indicates that the MMCN-151 neo-
epitope measured by this novel assay may be use-
ful for the evaluation of atherosclerosis. These data 
are in agreement with the literature showing that 
mimecan is implicated in the formation of athero-
sclerotic plaques.27 MMP12 is just one of a range of 
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MMPs  identified in atherosclerotic plaques where 
they are most often located in smooth muscle cells, 
macrophages and macrophage foam cells bordering 
the fibrous cap and within plaque shoulders.8,28–30 
A  gelatinase-family member, MMP-9, has been shown 
to have an effect on the size and composition of ath-
erosclerotic plaques.30 MMP-12, which is also known 
as elastase, is of special interest due to its selective 
secretion by macrophages.10,30,31 MMP-12 has also 
been shown to accelerate the initiation of atheroscle-
rosis and progression of fatty streaks.32
We previously found that both MMP-9 and -12 
generate the MMCN-151 fragment in cleavages of 
human atherosclerotic plaque material (unpublished 
data). The in vitro-cleaved purified mimecan and 
the lack of fragments we identified using the cur-
rent ELISA might be due to the fact that 72 hours of 
cleavage resulted in further destruction of the neo-
epitope by MMP-9. Further in vitro, time-dependent 
experiments are needed to investigate whether other 
proteases, including MMP-9, are able to generate the 
MMCN-151 fragment of mimecan.
Remarkably, we did not observe a correlation 
between levels of the MMCN-151 marker and 
plasma cholesterol in control or ApoE KO mice. 
These data suggest that the specific degradation 
of mimecan in atherosclerotic tissue might reflect 
very early pathological changes in the arteries, 
before plasma cholesterol levels begin to increase. 
 Moreover, it is interesting that we found no differ-
ence in MMCN-151 plasma levels between ApoE 
KO and control mice fed a normal diet. However, 
we saw that the increase in MMCN-151 is not medi-
ated by a high cholesterol diet, since only ApoE KO 
mice had elevated plasma biomarker levels. More-
over, it is interesting that we found no difference in 
MMCN-151 plasma levels in ApoE KO and control 
mice which received normal diet as we have seen 
previously with our collagen III, CO3-610 urine 
biomarker where significant biomarker increase was 
demonstrated in ApoE KO mice fed standard rodent 
chow.33 However, we have seen that the increase in 
MMCN-151 in ApoE KO mice seems to be medi-
ated by a high cholesterol diet, whereas no signifi-
cant increase in the circulating levels of MMCN-151 
were observed in control mice when comparing the 
two diet regimens.
In conclusion, we developed a technically robust 
competitive assay using a specific monoclonal anti-
body for the detection in human, rat and mouse sera 
and plasma of MMCN-151, a fragment of mimecan 
derived from MMP-12 degradation. We demonstrated 
that MMCN-151 was significantly elevated in ApoE 
KO mice fed a HFD for 20 weeks in comparison with 
control mice.
More studies, in particular human longitudinal 
studies, are needed to further evaluate the potential 
of this marker in cardiovascular diseases associated 
with underlying atherosclerosis. Lastly, this marker 
may provide additional insights into mimecan and its 
function in both healthy and diseased states.
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